Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Oncology

Standard of Care Treatment Strategies for NENs

At a Glance

Treatment for neuroendocrine neoplasms (NENs) depends heavily on the tumor's grade and hormone receptor status. Standard options include somatostatin analogs to control hormones, surgical debulking, targeted PRRT radiation, and specific chemotherapy regimens for aggressive cases.

Treating a neuroendocrine neoplasm (NEN) is not a “one-size-fits-all” process. Because these tumors range from slow-growing to very aggressive, your medical team will tailor your strategy based on the tumor’s grade, whether it has somatostatin receptors (SSTRs), and your overall symptoms.

Managing the “Hormone Engine” with SSAs

For many patients with well-differentiated, low-grade (G1 or G2) tumors, the first line of defense is often a Somatostatin Analog (SSA) [1][2]. Common SSAs include octreotide and lanreotide.

  • How they work: These drugs act like a “brake” on the tumor. They bind to the somatostatin receptors on the cell surface to slow down tumor growth and stop the overproduction of hormones that cause symptoms like flushing and diarrhea [1][3].
  • Important Side Effects: It is important to know that SSAs carry a high risk of causing gallstones or biliary sludge over time. Many surgeons will remove the gallbladder as a preventative measure if you are already having abdominal surgery.

The Role of Surgery and “Debulking”

Surgery remains a cornerstone of NEN treatment. While the goal is often to remove the entire tumor, NENs are unique because even partial removal—called debulking or cytoreduction—can be highly beneficial [4][5].

⚠️ Safety Warning: Carcinoid Crisis. If you have a functional tumor (like one causing Carcinoid Syndrome), invasive procedures, biopsies, or anesthesia can trigger a massive, life-threatening release of hormones called a “carcinoid crisis.” It is essential to advocate for yourself and ensure your surgical and anesthesia teams administer intravenous (IV) octreotide before and during any procedure to prevent this.

  • The 70% Rule: In cases where the cancer has spread to the liver, surgeons often aim to remove at least 70% of the visible tumor [4][6].
  • Benefits: Successful debulking is associated with improved survival and better control of hormonal symptoms, even if some cancer remains [4][7].

Precision Radiotherapy: PRRT

Peptide Receptor Radionuclide Therapy (PRRT) is a form of “molecularly targeted” radiation. The most common version uses a radioactive isotope called Lutetium-177 DOTATATE [8][9].

  • The Mechanism: The drug travels through the blood and latches onto the SSTRs on the tumor cells. Once attached, it delivers a high dose of radiation directly into the tumor while sparing most healthy tissue [8][10].
  • Safety Protocols: Because the radiation is cleared through your kidneys, you will receive a mandatory amino acid infusion during treatment to protect your renal function. You will also need regular blood tests to monitor for bone marrow suppression.
  • New Standards: While historically used after other treatments failed, recent research (the NETTER-2 trial) suggests that PRRT may be an effective first-line treatment for patients with advanced G2 or G3 tumors [11][12].

Targeted and Biological Therapies

If a tumor continues to grow despite SSAs, your doctor may suggest “targeted” oral medications:

  • Everolimus: An mTOR inhibitor that blocks a specific protein involved in cancer cell division and growth [13][9].
  • Sunitinib: A tyrosine kinase inhibitor that prevents tumors from growing the new blood vessels they need to survive. Note that sunitinib is primarily approved and utilized specifically for pancreatic NETs (pNETs) [9][3].

Treating Grade 3 (G3) NETs

It is critical to know that Grade 3 NETs (well-differentiated) require a different approach than highly aggressive NECs. They may be treated with targeted chemotherapies like CAPTEM (capecitabine and temozolomide) or PRRT, rather than the broad, intensive platinum-based regimens used for NECs [14][15].

Treating High-Grade Aggressive Disease (NEC)

The treatment for poorly-differentiated neuroendocrine carcinomas (NECs) is very different from that for slow-growing tumors. Because NEC cells divide rapidly, they are often more sensitive to traditional chemotherapy [16][17].

  • First-Line: The standard treatment is typically a “platinum-based” chemotherapy duo, such as cisplatin or carboplatin combined with etoposide [16][18].
  • Second-Line: If the first treatment stops working, regimens like FOLFIRI (a combination of three chemotherapy drugs) may be used [19][20].

Common questions in this guide

How do somatostatin analogs (SSAs) treat NENs?
Somatostatin analogs, like octreotide and lanreotide, act as a brake on the tumor. They bind to specific receptors on the tumor cells to slow their growth and stop the overproduction of hormones that cause symptoms like flushing and diarrhea.
What is tumor debulking surgery for neuroendocrine tumors?
Debulking is the surgical removal of as much of the tumor as possible, often aiming for at least 70 percent removal. Even if the entire cancer cannot be removed, debulking can significantly improve survival and help control severe hormonal symptoms.
How can I prevent a carcinoid crisis during surgery or a biopsy?
Invasive procedures, biopsies, and anesthesia can trigger a massive release of tumor hormones called a carcinoid crisis. To prevent this life-threatening reaction, you should advocate for your medical team to administer intravenous octreotide before and during your procedure.
What is PRRT and when is it used for neuroendocrine tumors?
PRRT is a targeted therapy that uses a drug traveling through the bloodstream to deliver high-dose radiation directly to tumor cells. Recent research shows it may be a highly effective first-line treatment for patients with certain advanced Grade 2 or Grade 3 tumors.
What is the difference in treating Grade 3 NETs versus aggressive NECs?
Grade 3 neuroendocrine tumors are often treated with targeted chemotherapies or PRRT because they are well-differentiated. In contrast, poorly-differentiated neuroendocrine carcinomas (NECs) grow rapidly and are typically treated with intense, platinum-based chemotherapy drugs.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my tumor grade and SSTR status, what is the recommended first-line treatment?
  2. 2.If I need surgery or a biopsy, what is the protocol for administering IV octreotide to prevent a Carcinoid Crisis?
  3. 3.If I start on a Somatostatin Analog (SSA), how will we monitor for gallstones and manage them if they occur?
  4. 4.Does the recent NETTER-2 study data make PRRT a first-line option for my specific grade of tumor?
  5. 5.For my high-grade diagnosis, are we using a platinum-based chemotherapy or a different combination like CAPTEM?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (20)
  1. 1

    New and Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors.

    Phan AT, Kunz PL, Reidy-Lagunes DL

    Clinical advances in hematology & oncology : H&O 2015; (13(5 Suppl 5)):1-18; quiz 1 p following 18.

    PMID: 26430956
  2. 2

    Treatment Patterns and Health Resource Use Among Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors Treated at a Tertiary Referral Center.

    Jalbert JJ, Casciano R, Meng J, et al.

    The oncologist 2020; (25(4)):e644-e650 doi:10.1634/theoncologist.2019-0691.

    PMID: 31999024
  3. 3

    What have we learnt from the past - would treatment decisions for GEP-NET patients differ between 2012 to 2016 by the new recommendations in 2022?

    Stiefel R, Lehmann K, Winder T, Siebenhüner AR

    BMC cancer 2023; (23(1)):148 doi:10.1186/s12885-023-10567-1.

    PMID: 36782152
  4. 4

    Effective cytoreduction can be achieved in patients with numerous neuroendocrine tumor liver metastases (NETLMs).

    Scott AT, Breheny PJ, Keck KJ, et al.

    Surgery 2019; (165(1)):166-175 doi:10.1016/j.surg.2018.04.070.

    PMID: 30343949
  5. 5

    Aggressive Surgical Approach to the Management of Neuroendocrine Tumors: A Report of 1,000 Surgical Cytoreductions by a Single Institution.

    Woltering EA, Voros BA, Beyer DT, et al.

    Journal of the American College of Surgeons 2017; (224(4)):434-447 doi:10.1016/j.jamcollsurg.2016.12.032.

    PMID: 28088602
  6. 6

    Liver-directed surgery of neuroendocrine metastases: What is the optimal strategy?

    Maxwell JE, Sherman SK, O'Dorisio TM, et al.

    Surgery 2016; (159(1)):320-33.

    PMID: 26454679
  7. 7

    Value of Surgical Cytoreduction in Patients with Small Intestinal Neuroendocrine Tumors Metastatic to the Liver and Peritoneum.

    Gudmundsdottir H, Fogliati A, Grotz TE, et al.

    Annals of surgical oncology 2024; (31(8)):5370-5376 doi:10.1245/s10434-024-15316-7.

    PMID: 38689169
  8. 8

    Neuroendocrine Tumors and Peptide Receptor Radionuclide Therapy: When Is the Right Time?

    Hope TA, Pavel M, Bergsland EK

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022; (40(24)):2818-2829 doi:10.1200/JCO.22.00176.

    PMID: 35649195
  9. 9

    The State of Peptide Receptor Radionuclide Therapy and Its Sequencing among Current Therapeutic Options for Gastroenteropancreatic Neuroendocrine Tumors.

    Raymond LM, Korzun T, Kardosh A, et al.

    Neuroendocrinology 2021; (111(11)):1086-1098 doi:10.1159/000516015.

    PMID: 33744879
  10. 10

    Somatostatin Receptor 2-Targeting Compounds.

    Smit Duijzentkunst DA, Kwekkeboom DJ, Bodei L

    Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2017; (58(Suppl 2)):54S-60S doi:10.2967/jnumed.117.191015.

    PMID: 28864613
  11. 11

    [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study.

    Singh S, Halperin D, Myrehaug S, et al.

    Lancet (London, England) 2024; (403(10446)):2807-2817 doi:10.1016/S0140-6736(24)00701-3.

    PMID: 38851203
  12. 12

    Cost-Effectiveness of [177Lu]Lu-DOTATATE for the Treatment of Newly Diagnosed Advanced Gastroenteropancreatic Neuroendocrine Tumors: An Analysis Based on Results of the NETTER-2 Trial.

    Holzgreve A, Unterrainer LM, Tiling M, et al.

    Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2025; (66(7)):1075-1081 doi:10.2967/jnumed.124.269416.

    PMID: 40473457
  13. 13

    Impact of multikinase inhibitors in reshaping the treatment of advanced gastroenteropancreatic neuroendocrine tumors.

    Siebenhüner AR, Refardt J, Nicolas GP, et al.

    Endocrine-related cancer 2025; (32(6)).

    PMID: 40392078
  14. 14

    Well-Differentiated Grade 3 Neuroendocrine Tumors: Characteristics, Treatments, and Outcomes From a Population-Based Study.

    Boutin M, Mathews A, Badesha J, et al.

    Pancreas 2022; (51(7)):756-762 doi:10.1097/MPA.0000000000002100.

    PMID: 36395400
  15. 15

    Patterns and outcomes of current antitumor therapy for high-grade neuroendocrine neoplasms: perspective of a tertiary referral center.

    Melhorn P, Spitzer J, Adel T, et al.

    Journal of cancer research and clinical oncology 2025; (151(2)):86 doi:10.1007/s00432-025-06126-9.

    PMID: 39971811
  16. 16

    Management of high-grade neuroendocrine neoplasms: impact of functional imaging.

    Islam O, Sarti K, Verbruggen L, et al.

    Endocrine-related cancer 2025; (32(4)).

    PMID: 39888333
  17. 17

    Etoposide and cisplatin versus irinotecan and cisplatin as the first-line therapy for patients with advanced, poorly differentiated gastroenteropancreatic neuroendocrine carcinoma: A randomized phase 2 study.

    Zhang P, Li J, Li J, et al.

    Cancer 2020; (126 Suppl 9()):2086-2092 doi:10.1002/cncr.32750.

    PMID: 32293725
  18. 18

    Future therapeutic strategies in the treatment of extrapulmonary neuroendocrine carcinoma: a review.

    Robinson MD, Livesey D, Hubner RA, et al.

    Therapeutic advances in medical oncology 2023; (15()):17588359231156870 doi:10.1177/17588359231156870.

    PMID: 36872945
  19. 19

    Bevacizumab plus FOLFIRI after failure of platinum-etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial.

    Walter T, Lievre A, Coriat R, et al.

    The Lancet. Oncology 2023; (24(3)):297-306 doi:10.1016/S1470-2045(23)00001-3.

    PMID: 36739879
  20. 20

    Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): a study protocol.

    Bongiovanni A, Liverani C, Pusceddu S, et al.

    BMJ open 2020; (10(7)):e034393 doi:10.1136/bmjopen-2019-034393.

    PMID: 32690499

This page provides general information about standard treatments for neuroendocrine neoplasms (NENs). It is not medical advice; always consult your oncology team to determine the safest and most effective treatment plan for your specific tumor.

Get notified when new evidence is published on Neuroendocrine neoplasm.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.